148 related articles for article (PubMed ID: 15647214)
1. Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator.
Hlatky MA; Sanders GD; Owens DK
Health Aff (Millwood); 2005; 24(1):42-51. PubMed ID: 15647214
[TBL] [Abstract][Full Text] [Related]
2. Implantable cardioverter defibrillators: an excellent case study.
Stanton MS
Health Aff (Millwood); 2005; 24(1):52-4. PubMed ID: 15647215
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
4. Preventing sudden death: implantable cardioverter-defibrillators in elderly cardiac patients.
Groeneveld PW
LDI Issue Brief; 2008; 13(6):1-4. PubMed ID: 18613344
[TBL] [Abstract][Full Text] [Related]
5. Referring patients for consideration of device treatment of sudden cardiac death and heart failure: incorporating evidence-based therapies within the Canadian health care system.
Gillis AM
Can J Cardiol; 2005 May; 21 Suppl A():25A-30A. PubMed ID: 15953941
[TBL] [Abstract][Full Text] [Related]
6. Shock treatment. Medicare's coverage of implantable defibrillators adds jolt to electrophysiology specialty, device sales.
Becker C
Mod Healthc; 2005 May; 35(19):34, 36. PubMed ID: 15929257
[No Abstract] [Full Text] [Related]
7. The high cost of implantable defibrillators.
Hlatky MA; Mark DB
Eur Heart J; 2007 Feb; 28(4):388-91. PubMed ID: 17032689
[TBL] [Abstract][Full Text] [Related]
8. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
Barold HS
Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
[TBL] [Abstract][Full Text] [Related]
9. Expenditure and value for money: the challenge of implantable cardioverter defibrillators.
Boriani G; Biffi M; Martignani C; Diemberger I; Valzania C; Bertini M; Branzi A
QJM; 2009 May; 102(5):349-56. PubMed ID: 19276209
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
[TBL] [Abstract][Full Text] [Related]
11. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.
Shah B; Hernandez AF; Liang L; Al-Khatib SM; Yancy CW; Fonarow GC; Peterson ED;
J Am Coll Cardiol; 2009 Feb; 53(5):416-22. PubMed ID: 19179199
[TBL] [Abstract][Full Text] [Related]
12. Benefits of the implantable cardioverter-defibrillator.
Epstein AE
J Am Coll Cardiol; 2008 Sep; 52(14):1122-7. PubMed ID: 18804737
[TBL] [Abstract][Full Text] [Related]
13. Cost of preimplantation cardiac imaging in patients referred for a primary-prevention implantable cardioverter-defibrillator.
Krahn AD; Hoch JS; Rockx MA; Leong-Sit P; Gula LJ; Yee R; Skanes AC; Klein GJ
Am J Cardiol; 2008 Sep; 102(5):588-92. PubMed ID: 18721517
[TBL] [Abstract][Full Text] [Related]
14. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
15. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004.
Al-Khatib SM; Sanders GD; Mark DB; Lee KL; Bardy GH; Bigger JT; Buxton AE; Connolly S; Kadish A; Moss A; Feldman AM; Ellenbogen KA; Singh S; Califf RM;
Am Heart J; 2005 Jun; 149(6):1020-34. PubMed ID: 15976783
[TBL] [Abstract][Full Text] [Related]
16. The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.
Proclemer A; Ghidina M; Cicuttini G; Gregori D; Fioretti PM
Ital Heart J; 2005 Mar; 6(3):272-80. PubMed ID: 15875520
[TBL] [Abstract][Full Text] [Related]
17. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making.
McGregor M; Chen J
Can J Cardiol; 2004 Oct; 20(12):1199-204. PubMed ID: 15494771
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials update: sudden cardiac death prevention by implantable device therapy.
Finch NJ; Leman RB
Crit Care Nurs Clin North Am; 2005 Mar; 17(1):33-8, x. PubMed ID: 15749399
[TBL] [Abstract][Full Text] [Related]
19. Implantable or external defibrillators for individuals at increased risk of cardiac arrest: where cost-effectiveness hits fiscal reality.
Cram P; Katz D; Vijan S; Kent DM; Langa KM; Fendrick AM
Value Health; 2006; 9(5):292-302. PubMed ID: 16961547
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
